FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894563559> ?p ?o ?g. }

• W2894563559 abstract "Abstract Background Omadacycline (OMC) is a novel aminomethylcycline with activity against Gram-positive, many Gram-negative, anaerobic, and atypical pathogens. It is in clinical development as once-daily oral (PO) and intravenous (IV) monotherapy for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). Cumulative safety results from Phase 3 clinical trials are reported. Methods This pooled safety analysis is based on 2,150 subjects: OASIS-1 (N = 645), OASIS-2 (N = 735) in ABSSSI; OPTIC (N = 770) in CABP. Comparators were linezolid (LZD) 600 mg IV then PO in ABSSSI (n = 689); moxifloxacin (MOX) 400 mg IV then PO in CABP (n = 388). Safety parameters included treatment-emergent adverse events (TEAEs), laboratory evaluations, vital signs, and electrocardiogram (ECG) findings. Results A total of 1,073 subjects received OMC: 705 received OMC IV then PO (ABSSSI, n = 323; CABP, n = 382); 368 received OMC PO only for ABSSSI. Overall, 60.6% were male and 91.6% white; mean age ranges were 44.7–45.1 and 60.9–62.1 years in ABSSSI and CABP studies, respectively. TEAEs were observed in 47.5% (OMC), 41.2% (LZD), and 48.5% (MOX) of subjects, with gastrointestinal events the most common TEAEs. Serious TEAEs were low (3.6% OMC, 1.9% LZD, 6.7% MOX). Nausea (14.9% OMC, 8.7% LZD, 5.4% MOX) and vomiting (8.3% OMC, 3.9% LZD, 1.5% MOX) were the most frequently reported TEAEs. Diarrhea was observed in 2.4% OMC, 2.9% LZD, and 8.0% MOX subjects, with no cases of Clostridium difficile in OMC-treated subjects. Most TEAEs were mild to moderate and did not result in study drug discontinuation (3.1% OMC, 1.5% LZD, 7.0% MOX); 4 OMC, 1 LZD, and 0 MOX subjects discontinued for nausea and vomiting. Frequency of hepatic TEAEs was similar for OMC, LZD, and MOX: 4.3% OMC, 4.1% LZD, and 4.5% MOX subjects had post-baseline ALT &gt;3× upper limit of normal. Vital signs and ECGs had comparable clinically notable values post-baseline in each treatment group. Known tetracycline class adverse events such as fungal infections were similar in all groups. Conclusion Pooled analyses demonstrate a favorable OMC safety profile, consistent with its tetracycline heritage. OMC was generally well tolerated in subjects with ABSSSI and CABP, with infrequent treatment discontinuations. Disclosures T. M. File Jr., BioMerieux: Consultant, Consulting fee; Curetis: Consultant, Consulting fee; Melinta Therapeutics: Consultant, Consulting fee; Merck: Consultant, Consulting fee; Motif Bio: Consultant, Consulting fee; Nabriva Therapeutics: Consultant and Investigator, Consulting fee and Research grant; Paratek Pharmaceuticals: Consultant, Consulting fee; Pfizer: Consultant, Consulting fee. T. Van Der Poll, Paratek Pharmaceuticals: Consultant, Consulting fee. P. McGovern, Paratek Pharmaceuticals: Employee, Salary. E. Tzanis, Paratek Pharmaceuticals: Employee, Salary." @default.
• W2894563559 created "2018-10-12" @default.
• W2894563559 creator A5008776510 @default.
• W2894563559 creator A5025379878 @default.
• W2894563559 creator A5043695605 @default.
• W2894563559 creator A5048965254 @default.
• W2894563559 creator A5053622214 @default.
• W2894563559 creator A5062874736 @default.
• W2894563559 date "2018-11-01" @default.
• W2894563559 modified "2023-10-16" @default.
• W2894563559 title "1374. Integrated Safety Summary of Omadacycline: A Novel Aminomethylcycline Antibiotic" @default.
• W2894563559 doi "https://doi.org/10.1093/ofid/ofy210.1205" @default.
• W2894563559 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6252771" @default.
• W2894563559 hasPublicationYear "2018" @default.
• W2894563559 type Work @default.
• W2894563559 sameAs 2894563559 @default.
• W2894563559 citedByCount "1" @default.
• W2894563559 countsByYear W28945635592019 @default.
• W2894563559 crossrefType "journal-article" @default.
• W2894563559 hasAuthorship W2894563559A5008776510 @default.
• W2894563559 hasAuthorship W2894563559A5025379878 @default.
• W2894563559 hasAuthorship W2894563559A5043695605 @default.
• W2894563559 hasAuthorship W2894563559A5048965254 @default.
• W2894563559 hasAuthorship W2894563559A5053622214 @default.
• W2894563559 hasAuthorship W2894563559A5062874736 @default.
• W2894563559 hasBestOaLocation W28945635591 @default.
• W2894563559 hasConcept C126322002 @default.
• W2894563559 hasConcept C197934379 @default.
• W2894563559 hasConcept C2778715236 @default.
• W2894563559 hasConcept C2778836808 @default.
• W2894563559 hasConcept C2778980435 @default.
• W2894563559 hasConcept C2779489039 @default.
• W2894563559 hasConcept C2780580376 @default.
• W2894563559 hasConcept C2780852908 @default.
• W2894563559 hasConcept C2781414143 @default.
• W2894563559 hasConcept C501593827 @default.
• W2894563559 hasConcept C523546767 @default.
• W2894563559 hasConcept C54355233 @default.
• W2894563559 hasConcept C71924100 @default.
• W2894563559 hasConcept C86803240 @default.
• W2894563559 hasConcept C89423630 @default.
• W2894563559 hasConcept C90924648 @default.
• W2894563559 hasConceptScore W2894563559C126322002 @default.
• W2894563559 hasConceptScore W2894563559C197934379 @default.
• W2894563559 hasConceptScore W2894563559C2778715236 @default.
• W2894563559 hasConceptScore W2894563559C2778836808 @default.
• W2894563559 hasConceptScore W2894563559C2778980435 @default.
• W2894563559 hasConceptScore W2894563559C2779489039 @default.
• W2894563559 hasConceptScore W2894563559C2780580376 @default.
• W2894563559 hasConceptScore W2894563559C2780852908 @default.
• W2894563559 hasConceptScore W2894563559C2781414143 @default.
• W2894563559 hasConceptScore W2894563559C501593827 @default.
• W2894563559 hasConceptScore W2894563559C523546767 @default.
• W2894563559 hasConceptScore W2894563559C54355233 @default.
• W2894563559 hasConceptScore W2894563559C71924100 @default.
• W2894563559 hasConceptScore W2894563559C86803240 @default.
• W2894563559 hasConceptScore W2894563559C89423630 @default.
• W2894563559 hasConceptScore W2894563559C90924648 @default.
• W2894563559 hasLocation W28945635591 @default.
• W2894563559 hasLocation W28945635592 @default.
• W2894563559 hasLocation W28945635593 @default.
• W2894563559 hasOpenAccess W2894563559 @default.
• W2894563559 hasPrimaryLocation W28945635591 @default.
• W2894563559 hasRelatedWork W1992859550 @default.
• W2894563559 hasRelatedWork W2144950349 @default.
• W2894563559 hasRelatedWork W2315697555 @default.
• W2894563559 hasRelatedWork W2416070876 @default.
• W2894563559 hasRelatedWork W2423548930 @default.
• W2894563559 hasRelatedWork W2434191050 @default.
• W2894563559 hasRelatedWork W2995648968 @default.
• W2894563559 hasRelatedWork W3048122021 @default.
• W2894563559 hasRelatedWork W4233958714 @default.
• W2894563559 hasRelatedWork W4240455838 @default.
• W2894563559 isParatext "false" @default.
• W2894563559 isRetracted "false" @default.
• W2894563559 magId "2894563559" @default.
• W2894563559 workType "article" @default.